BioLineRx (BLRX) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Universe Pharmaceuticals (UPC) has outperformed BioLineRx (BLRX) over the past year, losing 68.2% versus a loss of 70.3%. Over five years, BLRX leads with a -99.1% price change compared with -100.0% for UPC. Universe Pharmaceuticals is the larger company by market cap ($5.4 million vs $4.8 million), about 1.1 times the size.
Universe Pharmaceuticals converts more of its revenue into profit, with a net margin of -20.6% versus -171.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | UPC |
|---|---|---|
| Share price | $0.9639 | $1.08 |
| Market cap | $4.80M | $5.43M |
| 1-day change | -8.20% | -20.59% |
| YTD return | -65.20% | -71.65% |
| 1-year return | -70.34% | -68.24% |
| 5-year return | -99.07% | -99.99% |
| EPS (TTM) | $0.00 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.18M | $17.86B |
| Revenue growth (YoY) | -95.92% | -22.44% |
| Net income (latest FY) | $-2.03M | $-3.67B |
| Gross margin | 80.51% | 35.28% |
| Operating margin | -871.78% | -16.33% |
| Net margin | -171.69% | -20.56% |
| 52-week high | $3.95 | $17.96 |
| 52-week low | $0.78 | $1.05 |
| Distance from 52-week high | -75.60% | -93.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +2182.39% | — |
| Average volume | 23.43K | 176.76K |
| Shares outstanding | 4.98M | 5.01M |
| Employees | 20 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Universe Pharmaceuticals is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -171.7 cents for BioLineRx.
- Universe Pharmaceuticals grew revenue faster in its latest fiscal year (-22.44% vs -95.92%).
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
BLRX vs UPC FAQ
Which is bigger, BioLineRx or Universe Pharmaceuticals?
Universe Pharmaceuticals (UPC) is larger, with a market capitalization of $5.43M compared with $4.80M for BioLineRx (BLRX).
Which stock has performed better over the past year, BLRX or UPC?
UPC returned -68.24% over the past 12 months, compared with -70.34% for BLRX (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.